Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Cytek Biosciences Fourth Quarter 2023 Earnings Conference Call.
Cytek Biosciences Inc. (CTKB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 6,809,404 | $62,101,764 | 0.96% | |
| 2. | Hillhouse Capital Management Lei Zhang | 6,657,030 | $60,712,114 | 1.22% | |
| 3. | Alyeska Investment Group Anand Parekh | 100,000 | $912,000 | 0% | |
| 4. | AQR Capital Management Cliff Asness | 56,206 | $512,599 | +44% | 0% |
| 5. | Zevenbergen Capital Investments Nancy Zevenbergen | 42,300 | $385,776 | +5% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.27 | 241,727 | Large Shareholder, Director | 13,381,054 | 2022-03-15 | Filing | |
| $12.35 | 342,143 | Large Shareholder, Director | 13,139,327 | 2022-03-14 | Filing | |
| $12.77 | 337,492 | Director | 12,797,184 | 2022-03-11 | Filing | |
| $12.95 | 256,992 | Director | 12,459,692 | 2022-03-10 | Filing | |
| $12.99 | 40,154 | Director | 12,202,700 | 2022-03-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.01 | 400 | 6,008,502 | 2024-04-09 | Filing | ||
| $7.00 | 1,500 | 6,008,902 | 2024-04-09 | Filing | ||
| $6.71 | 20,000 | 6,010,402 | 2024-03-19 | Filing | ||
| $6.77 | 20,000 | 6,030,402 | 2024-03-18 | Filing | ||
| $9.50 | 3,000 | Officer | 93,400 | 2023-12-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,779,753 | $162,151,347 | 0% | |
| 2. | 12,016,325 | $109,588,884 | 1.64% | |
| 3. | 11,890,700 | $108,443,184 | 0% | |
| 4. | 3,997,769 | $36,459,653 | 0% | |
| 5. | 2,456,535 | $22,405,878 | 0% |
News See All
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Cytek Biosciences Third Quarter 2023 Earnings Conference Call.
Hedge Fund and Insider Trading News: Steve Cohen, Cathie Wood, Caledonia Investments, Vapotherm Inc (VAPO), Inhibrx, Inc. (INBX), and More
The cryptocurrency industry eagerly awaits the next decision from the Securities and Exchange Commission after a U.S. court ruling a week ago regarding Grayscale Investments (GBTC).
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Cytek Biosciences Second Quarter 2023 Earnings Conference Call.
What Makes RGA Investments Hold Cytek Biosciences (CTKB)?
Investment management company RGA Investment Advisors recently released its first-quarter 2023 investor letter. A copy of the same can be downloaded here.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and thank you for standing by. Welcome to the Cytek Biosciences First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Should You Invest in Cytek Biosciences (CTKB) for a Long-Term?
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Strategy” Q3 2022 investor letter. A copy of the same can be downloaded here.
Can the New Diagnostic Tools Boost Cytek Biosciences (CTKB)'s Valuation?
Investment management company RGA Investment Advisors recently released its third-quarter 2022 investor letter. A copy of the same can be downloaded here.
RGAIA Investment: "Cytek Biosciences (CTKB) is Profitable Today & Will be Even More So in the Future"
RGAIA Investment Advisors, an independent, privately owned asset management firm recently published its second-quarter 2022 investor letter – a copy of which can be downloaded here.
RGA Investment Advisors Expects Surprising Returns From Cytek Biosciences (CTKB)
Investment management company RGA Investment Advisors recently released its second-quarter 2022 investor letter. A copy of the same can be downloaded here.
Billionaire Hedge Funds
